Brean Murray Carret & Co. Maintains a 'Buy' on Gilead Sciences (GILD); Stribild Sales to Exceed $2.7 Billion in '19

Brean Murray Carret & Co. maintains a 'Buy' on Gilead Sciences (NASDAQ: GILD) price target of $60.00.

Analyst, Brian Skorney, said, "Stibild's approval comes as no surprise but we note pricing ($2,342.78 per 30 day script) that is materially higher than the company's other single-pill, total therapy options Atripla ($1,734.14 per 30 day) and Complera ($1,830 per 30 day) but in line with other PI-based and Integrase inhibitory-based approaches. We believe that the strong sales growth of Complera signifies a desire in the HIV community for alternative treatment options and with a single-pill, one daily integrase inhibitor-based combo we feel Stribild will be even more successful in its initial penetration.

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $57.19 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform